Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
FOMX was delisted on the 6th of March, 2020.
48 hedge funds and large institutions have $130M invested in Foamix Pharmaceuticals Ltd. Ordinary Shares in 2017 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
9% more capital invested
Capital invested by funds: $120M → $130M (+$10.3M)
7% more funds holding
Funds holding: 45 → 48 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
44% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 18
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $151K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$2.3M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
+$1.01M |
| 3 |
Handelsbanken Fonder
Stockholm,
Sweden
|
+$602K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$566K |
| 5 |
IIA
IPG Investment Advisors
San Diego,
California
|
+$370K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$1.9M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.1M |
| 3 |
Goldman Sachs
New York
|
-$519K |
| 4 |
SAM
Senzar Asset Management
New York
|
-$517K |
| 5 |
BlackRock
New York
|
-$370K |
FOMX Hedge Fund Activity: Q4 2017 in Review
48 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) for Q4 2017, worth a combined $130M — up 8.6% from $120M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new FOMX positions and 5 closed out — a net gain of 3 holders — while 10 added to existing stakes and 18 trimmed.
The largest buyer was International Biotechnology Trust, opening a new position worth an estimated $2.3M. The largest seller was Deerfield Management, cutting an estimated $1.9M.
- 48 institutional investors held Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) as of Q4 2017, up from 45 in Q3 2017.
- Funds reported $130M of Foamix Pharmaceuticals Ltd. Ordinary Shares stock for Q4 2017, up 8.6% quarter-over-quarter.
- 8 funds opened new Foamix Pharmaceuticals Ltd. Ordinary Shares positions in Q4 2017 and 5 closed out, a net change of +3 holders.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares buyer in Q4 2017 was International Biotechnology Trust, an estimated $2.3M added.
- The largest Foamix Pharmaceuticals Ltd. Ordinary Shares seller in Q4 2017 was Deerfield Management, an estimated $1.9M sold.
Based on aggregated 13F filings for Q4 2017.